Literature DB >> 7554013

Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting.

.   

Abstract

Influenza has been a significant public health problem worldwide, with three pandemics during the past century. Immunization is the most effective measure to control an influenza pandemic. Since rapid production of large amounts of influenza vaccine depends on the availability of fertile hens' eggs to grow the viruses, there is an urgent need for the development of alternative cell culture systems, which would allow rapid scale-up of production in the event of a pandemic. This WHO meeting discussed the results of studies from several laboratories on the cultivation of influenza viruses in stable cell lines, and made recommendations for further work.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7554013      PMCID: PMC2486787     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  8 in total

1.  GENETIC STUDIES OF INFLUENZA VIRUSES. II. PLAQUE FORMATION BY INFLUENZA VIRUSES IN A CLONE OF A VARIANT HUMAN HETEROPLOID CELL LINE.

Authors:  A SUGIURA; E D KILBOURNE
Journal:  Virology       Date:  1965-07       Impact factor: 3.616

2.  Evaluation of the new serum-free medium (MDSS2) for the production of different biologicals: use of various cell lines.

Authors:  O W Merten; J V Kierulff; N Castignolles; P Perrin
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

3.  Cell tropism of influenza virus mediated by hemagglutinin activation at the stage of virus entry.

Authors:  R Boycott; H D Klenk; M Ohuchi
Journal:  Virology       Date:  1994-09       Impact factor: 3.616

4.  Isolation and preliminary characterization of a highly cytolytic influenza B virus variant with an aberrant NS gene.

Authors:  T Tanaka; M Urabe; H Goto; K Tobita
Journal:  Virology       Date:  1984-06       Impact factor: 3.616

5.  Gene composition of high-yielding influenza vaccine strains obtained by recombination.

Authors:  M Baez; P Palese; E D Kilbourne
Journal:  J Infect Dis       Date:  1980-03       Impact factor: 5.226

6.  Impairment of multicycle influenza virus growth in Vero (WHO) cells by loss of trypsin activity.

Authors:  N V Kaverin; R G Webster
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

7.  Comparison of 10 influenza A (H1N1 and H3N2) haemagglutinin sequences obtained directly from clinical specimens to those of MDCK cell- and egg-grown viruses.

Authors:  E P Rocha; X Xu; H E Hall; J R Allen; H L Regnery; N J Cox
Journal:  J Gen Virol       Date:  1993-11       Impact factor: 3.891

8.  Genetic study of human cells in vitro. Carbohydrate variants from cultures of HeLa and conjunctival cells.

Authors:  R S CHANG
Journal:  J Exp Med       Date:  1960-02-01       Impact factor: 14.307

  8 in total
  12 in total

1.  Enhanced growth of influenza vaccine seed viruses in vero cells mediated by broadening the optimal pH range for virus membrane fusion.

Authors:  Shin Murakami; Taisuke Horimoto; Mutsumi Ito; Ryo Takano; Hiroaki Katsura; Masayuki Shimojima; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

Review 2.  Influenza vaccines. A reappraisal of their use.

Authors:  A M Palache
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

3.  Cell culture-derived flu vaccine: Present and future.

Authors:  Alberto Pérez Rubio; Jose María Eiros
Journal:  Hum Vaccin Immunother       Date:  2018-06-28       Impact factor: 3.452

4.  An MDCK cell culture-derived formalin-inactivated influenza virus whole-virion vaccine from an influenza virus library confers cross-protective immunity by intranasal administration in mice.

Authors:  Ahmad M Haredy; Nobuyuki Takenaka; Hiroshi Yamada; Yoshihiro Sakoda; Masatoshi Okamatsu; Naoki Yamamoto; Takeshi Omasa; Hisao Ohtake; Yasuko Mori; Hiroshi Kida; Koichi Yamanishi; Shigefumi Okamoto
Journal:  Clin Vaccine Immunol       Date:  2013-05-01

5.  Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.

Authors:  Christof David Vinnemeier; Johanna Fischer-Herr; Seetha Meyer; Katja Liebig; Wiebke Theeß; Gerd-Dieter Burchard; Jakob P Cramer
Journal:  Hum Vaccin Immunother       Date:  2013-11-15       Impact factor: 3.452

6.  Cell-based influenza vaccine: current production, halal status assessment, and recommendations towards Islamic-compliant manufacturing.

Authors:  Nurul Nadiah Zulkarnain; Nurina Anuar; Norliza Abd Rahman; Siti Rozaimah Sheikh Abdullah; Muhammad Nazir Alias; Mashitoh Yaacob; Zhongren Ma; Gongtao Ding
Journal:  Hum Vaccin Immunother       Date:  2021-02-04       Impact factor: 3.452

7.  Cell culture-based production of defective interfering particles for influenza antiviral therapy.

Authors:  Milena A Wasik; Luca Eichwald; Yvonne Genzel; Udo Reichl
Journal:  Appl Microbiol Biotechnol       Date:  2017-12-05       Impact factor: 4.813

Review 8.  Egg-Independent Influenza Vaccines and Vaccine Candidates.

Authors:  Ilaria Manini; Claudia Maria Trombetta; Giacomo Lazzeri; Teresa Pozzi; Stefania Rossi; Emanuele Montomoli
Journal:  Vaccines (Basel)       Date:  2017-07-18

Review 9.  The expanding role of mass spectrometry in the field of vaccine development.

Authors:  Vaneet Kumar Sharma; Ity Sharma; James Glick
Journal:  Mass Spectrom Rev       Date:  2018-05-31       Impact factor: 10.946

Review 10.  New Technologies for Influenza Vaccines.

Authors:  Steven Rockman; Karen L Laurie; Simone Parkes; Adam Wheatley; Ian G Barr
Journal:  Microorganisms       Date:  2020-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.